Shots:
- The P-III RECOVERY trial evaluating REGEN-COV (8,000 mg) vs usual care alone in seronegative patients with COVID-19 demonstrates 20% reduction in risk of death in patients failing to exhibit a natural antibody response
- The 1EPs showed 20% reduction in all-cause mortality, no longer significant effect on 28-day mortality on combining larger seropositive group (also those with unknown status) with seronegative patients
- Additionally, lower risk of composite EP progression of invasive mechanical ventilation or death was observed (30% vs 37%). The company will share new data with regulatory authorities & request FDA to expand the current EUA to other populations
Click here to read full press release/ article | Ref: PR Newswire | Image: The Print
The post Regeneron Reports Results of REGEN-COV (casirivimab and imdevimab) in P-III RECOVERY Trial for COVID-19 Patients first appeared on PharmaShots.
